[go: up one dir, main page]

WO1999013064A3 - Viral infection of cells using viral vectors - Google Patents

Viral infection of cells using viral vectors Download PDF

Info

Publication number
WO1999013064A3
WO1999013064A3 PCT/GB1998/002753 GB9802753W WO9913064A3 WO 1999013064 A3 WO1999013064 A3 WO 1999013064A3 GB 9802753 W GB9802753 W GB 9802753W WO 9913064 A3 WO9913064 A3 WO 9913064A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
viral
infecting
infected
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1998/002753
Other languages
French (fr)
Other versions
WO1999013064A2 (en
Inventor
Marc Feldmann
Brian Maurice John Foxwell
Fionula Mary Brennan
Jan Bondeson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Kennedy Institute of Rheumotology
Mathilda and Terence Kennedy Institute of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology, Mathilda and Terence Kennedy Institute of Rheumatology filed Critical Kennedy Institute of Rheumotology
Priority to JP2000510853A priority Critical patent/JP2001515716A/en
Priority to EP98942892A priority patent/EP1012321A2/en
Publication of WO1999013064A2 publication Critical patent/WO1999013064A2/en
Publication of WO1999013064A3 publication Critical patent/WO1999013064A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to an in vitro method for infecting one or more cells with a viral vector capable of transporting exogenous or recombinant nucleic acid into the cells to be infected, comprising the steps of: a) collecting the cells to be infected; b) treating the collected cells with at least one cytokine; and c) infecting the collected cells with a viral vector such as adenovirus. A method of infecting rheumatoid synovial cells and other cells comprising high levels of cell surface integrins is also disclosed.
PCT/GB1998/002753 1997-09-11 1998-09-11 Viral infection of cells using viral vectors Ceased WO1999013064A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000510853A JP2001515716A (en) 1997-09-11 1998-09-11 Viral infection of cells
EP98942892A EP1012321A2 (en) 1997-09-11 1998-09-11 Viral infection of cells using viral vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9719238.9 1997-09-11
GBGB9719238.9A GB9719238D0 (en) 1997-09-11 1997-09-11 Viral infection of cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09508350 A-371-Of-International 2000-04-07
US10/033,267 Continuation US20020177572A1 (en) 1997-09-11 2001-10-25 Viral infection of cells

Publications (2)

Publication Number Publication Date
WO1999013064A2 WO1999013064A2 (en) 1999-03-18
WO1999013064A3 true WO1999013064A3 (en) 1999-06-17

Family

ID=10818857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002753 Ceased WO1999013064A2 (en) 1997-09-11 1998-09-11 Viral infection of cells using viral vectors

Country Status (4)

Country Link
EP (1) EP1012321A2 (en)
JP (1) JP2001515716A (en)
GB (1) GB9719238D0 (en)
WO (1) WO1999013064A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922281D0 (en) * 1999-09-22 1999-11-17 Kennedy Rheumatology Inst Polymorphism
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779361A2 (en) * 1995-12-15 1997-06-18 F. Hoffmann-La Roche Ag Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779361A2 (en) * 1995-12-15 1997-06-18 F. Hoffmann-La Roche Ag Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
B. FOXWELL ET AL.,: "Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis alpha production in rheumatoid arthritis is NF-kappaB dependent", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 14, 1998, pages 8211 - 8215, XP002098099 *
BAEUERLE P A ET AL: "FUNCTION AND ACTIVATION OF NF-KappaB INTHE IMMUNE SYSTEM", ANNUAL REVIEW OF IMMUNOLOGY, vol. 12, 1994, pages 141 - 179, XP000612175 *
C. JOBIN ET AL.,: "Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappa-beta super-repressor in human intestinal epithelial cells.", JOURNAL OF INMUNOLOGY, vol. 160, no. 1, 1 January 1998 (1998-01-01), pages 410 - 418, XP002098101 *
C. JOBIN ET AL.,: "Potential novel therapy for the intestine: adenoviral mediated gene delivery of an NF-kappa super-repressor blocked proinflammatory gene expression in human intestinal epithelial cells", GASTROENTEROLOGY, vol. 112, no. (4 suppl.), 1997, pages pA1006, XP002098097 *
HADDADA H ET AL: "EFFICIENT ADENOVIRUS-MEDIATED GENE TRANSFER INTO HUMAN BLOOD MONOCYTE-DERIVED MACROPHAGES", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 195, no. 3, 30 September 1993 (1993-09-30), pages 1174 - 1183, XP002005682 *
H-G ZHANG ET AL.,: "Increased susceptibility of RA synovial cells to TNFalpha-mediated apoptosis after IKB dominate negative gene therapy", ARTHRITIS AND RHEUMATISM, vol. 41, no. (9 suppl.), 1 September 1998 (1998-09-01), pages ps96, XP002098100 *
M. FELDMAN ET AL.,: "Anti-TNFalpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases", TRANSPLANTATION PROCEEDINGS, vol. 30, no. 8, 1 December 1998 (1998-12-01), pages 4126 - 4127, XP002098301 *
PAHL H L ET AL: "The ER-overload response: activation of NF-kappaB", TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 22, no. 2, February 1997 (1997-02-01), pages 63-67, XP004050133 *
S. HUANG ET AL.,: "Upregulation of integrins alpha-v-beta-3 and alpha-v-beta-5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery", JOURNAL OF VIROLOGY, vol. 69, no. 4, 1995, pages 2257 - 2263, XP002098096 *
S.S. MAKAROV ET AL.,: "NF-kappa B as a target for anti-inflammatory gene therapy: Suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of I-kappa-B-alpha cDNA", GENE THERAPY, vol. 4, no. 8, 1997, pages 846 - 852, XP002098098 *

Also Published As

Publication number Publication date
GB9719238D0 (en) 1997-11-12
JP2001515716A (en) 2001-09-25
WO1999013064A2 (en) 1999-03-18
EP1012321A2 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
WO2000008191A3 (en) Herpes virus vectors for dendritic cells
EP0484374A4 (en) Rapid, versatile and simple system for expressing genes in eukaryotic cells
NO964445L (en) DNA sequence, vector, host cell and method for transfecting hematopoietic cells with exogenous DNA
CA2092680A1 (en) Epstein-barr virus sequences and protein thereof
NZ500740A (en) Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
NZ320276A (en) Method and preparations for stabilizing biological materials by drying methods without freezing
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
ZA979732B (en) Infectious clones of RNA viruses and vaccines and diagnostic assays derived therof.
CA2236968A1 (en) Accessory functions for use in recombinant aav virion production
HU9502949D0 (en) Polipeptides, polinucleotides, vectors and host cells, and vaccines against hepatitis virus infection, diagnostics, immunoassay and culturing methods
EP1923467A3 (en) Adenovirus vectors for gene therapy
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
EP0702716A4 (en) Ribozyme gene therapy for hiv infection and aids
WO2000053729A3 (en) Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
AUPN477695A0 (en) Gene therapy
CA2437962A1 (en) Method of extracting virus from cell culture
WO2001055362A3 (en) Hybrid adeno-retroviral vector for the transfection of cells
CA2306449A1 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
FR2606029B2 (en) VIRAL VECTOR AND RECOMBINANT DNA ENCODING VIA GLYCOPROTEIN CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING GLYCOPROTEIN, GLYCOPROTEIN OBTAINED, VACCINE AND ANTIBODY OBTAINED
WO1999013064A3 (en) Viral infection of cells using viral vectors
WO1999053047A3 (en) Porcine adenovirus type 3 genome
AU5318496A (en) Adenovirus vectors for gene therapy
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
ATE316139T1 (en) ATTENUATE EQUINOHERPESVIRUS
EP0326127A3 (en) Infectious bovine rhinotracheitis virus insertion mutants, vaccins containing same, and methods for the production and use of same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1998942892

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09508350

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998942892

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998942892

Country of ref document: EP